OrganoClick AB (FRA:0CF) Research & Development: €0.61 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0CF OrganoClick AB FRA:0CF
25 GF Score
Price €0.02
GF Value €0.11
! 4 Warning Signs
View Full Analysis

What is OrganoClick AB Research & Development?

OrganoClick AB FRA:0CF -10.37% 25 Research & Development is €0.61 Mil as of Mar. 2026. GuruFocus rates FRA:0CF with a GF Score™ of 25/100 and a GF Value™ of €0.11. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. OrganoClick AB's Research & Development for the three months ended in Mar. 2026 was €0.17 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.61 Mil.

OrganoClick AB  (FRA:0CF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

OrganoClick AB Research & Development Related Terms

OrganoClick AB Research & Development Historical Data

* Premium members only.

The historical data trend for OrganoClick AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OrganoClick AB Research & Development Chart

OrganoClick AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 1.11 0.60 0.52 0.58

OrganoClick AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.14 0.16 0.17
FRA:0CF
25GF Score
OrganoClick AB FRA:0CF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OrganoClick AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.61 Mil mean?
OrganoClick AB (FRA:0CF) has a Research & Development of €0.61 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on OrganoClick AB and its competitors.
Is OrganoClick AB's Research & Development too high?
OrganoClick AB's current Research & Development is €0.61 Mil. Overall, OrganoClick AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does OrganoClick AB's Research & Development compare to LIN and SHW?
OrganoClick AB's Research & Development of €0.61 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Chemicals company?
A good Research & Development depends on the Chemicals industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on OrganoClick AB and its competitors. OrganoClick AB's current Research & Development is €0.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrganoClick AB stock overvalued right now?
OrganoClick AB (FRA:0CF) has a current Research & Development of €0.61 Mil. The stock's GF Value™ is €0.11, compared to a current price of €0.02 — trading 78% below its estimated fair value. The current Research & Development is €0.61 Mil. OrganoClick AB's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For OrganoClick AB (FRA:0CF), the current Research & Development is €0.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OrganoClick AB (FRA:0CF) Overvalued in 2026?

Based on GuruFocus' analysis, OrganoClick AB stock appears to be undervalued. The current stock price of €0.02 is trading 78% below its estimated GF Value™ of €0.11.

Key valuation signals for FRA:0CF:

  • Research & Development: €0.61 Mil
  • GF Value™: €0.11 vs. price of €0.02 (78% below fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the FRA:0CF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OrganoClick AB Business Description

Other Exchanges ORGC:Sweden
Address Linjalvagen 9, Taby, SWE, SE-187 66
OrganoClick AB is involved in the chemicals industry. Its product portfolio includes green chemical technologies for creating water repellency, biobased binders for increasing the mechanical strength, and wood treatment products for resistance to fungal degradation and resistance to fire. It operates in four business areas Functional Wood, Green coatings & maintenance products, Nonwoven & technical textile, and Other. The group has a single operating segment.
25GF Score

Get the complete analysis for FRA:0CF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.11
GF Value